Enteropathic arthritis

Last updated 28 Mar 2026

Enteropathic Arthritis

Enteropathic arthritis (EnA) is a form of spondyloarthritis (SpA) occurring in association with inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis. It is one of the most common extra-intestinal manifestations of IBD, affecting 10–20% of patients. EnA encompasses both peripheral joint disease and axial (spinal/sacroiliac) involvement. Peripheral arthritis often parallels bowel disease activity, while axial disease may progress independently of gut inflammation.

Australian Epidemiology

Australia has among the highest rates of IBD in the world, with an estimated prevalence of 85,000 individuals affected. Crohn's disease affects approximately 1 in 250 Australians, and ulcerative colitis 1 in 200. Enteropathic arthritis is thus a significant musculoskeletal comorbidity encountered across gastroenterology and rheumatology practice. Diagnosis is often delayed given overlapping presentations with mechanical back pain and IBD-related musculoskeletal symptoms.

Pathophysiology

Gut-Joint Axis

The pathogenesis of EnA involves dysregulation of the gut-joint immune axis. Increased intestinal permeability in IBD allows translocation of microbial antigens and activated immune cells from the gut mucosa into the systemic circulation. These primed lymphocytes, particularly gut-homing T cells bearing α4β7 integrin, can traffic to synovial tissue and trigger joint inflammation. Shared mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression in both gut and joint vasculature facilitates lymphocyte trafficking to joints.

Genetic Factors

HLA-B27 is associated with axial EnA (present in 50–70% of axial cases) but less strongly with peripheral EnA. Other IBD-associated genes (NOD2/CARD15, IL-23R, TNF polymorphisms) contribute to susceptibility. The overlap between genetic risk factors for IBD and SpA supports a shared immunological pathway involving innate immune dysregulation, IL-17/IL-23 axis activation, and TNF-alpha overexpression.

Clinical Presentation

Peripheral Arthritis

Two patterns of peripheral joint involvement are recognised. Type 1 (pauciarticular) affects fewer than 5 large joints asymmetrically (knees, ankles, elbows, wrists), is acute and self-limiting, closely parallels IBD flares, and does not cause joint damage. Type 2 (polyarticular) affects 5 or more small joints symmetrically, resembles rheumatoid arthritis, runs a course independent of bowel activity, and may persist for months to years.

Axial Disease

Inflammatory back pain with morning stiffness, sacroiliitis on imaging, and spinal involvement similar to ankylosing spondylitis. May precede, coincide with, or follow IBD diagnosis. Axial disease often progresses independently of intestinal disease activity. Cervical and thoracic spine involvement possible in established disease.

Other Manifestations

Enthesitis — Achilles tendinopathy, plantar fasciitis
Dactylitis — sausage digit deformity
Uveitis — anterior, may be HLA-B27 associated
Erythema nodosum — skin nodules correlating with IBD activity
Pyoderma gangrenosum — severe skin ulceration

Investigations

Essential
Inflammatory Markers (ESR, CRP)
Elevated in active disease but may reflect bowel or joint activity. Useful for monitoring treatment response.
Essential
Full Blood Count
Anaemia of chronic disease common. Leucocytosis in active inflammation. Thrombocytosis reflects active IBD.
Essential
Pelvic X-ray / Sacroiliac Joints
Sacroiliitis (bilateral Grade 2 or higher) diagnostic of radiographic axial disease. May be normal in early disease.
Essential
MRI Sacroiliac Joints and Spine
Preferred for early axial EnA. STIR sequences detect bone marrow oedema (osteitis) before X-ray changes. Superior sensitivity for non-radiographic axial SpA.
Available
HLA-B27
Positive in 50–70% of axial EnA; less useful for peripheral EnA. Aids diagnosis when combined with clinical features.
Available
Rheumatoid Factor / Anti-CCP
Usually negative in EnA (type 2 peripheral arthritis may be seronegative). Helps differentiate from RA.
Referral
Colonoscopy / Faecal Calprotectin
Establish or confirm IBD diagnosis. Faecal calprotectin useful non-invasive marker of gut inflammation activity.

Disease Severity Assessment

MILD

Low Activity

Type 1 peripheral arthritis, 1–2 joints, functional, IBD quiescent

Managed with NSAIDs (if IBD permits) and physiotherapy

MODERATE

Moderate Activity

Type 2 polyarthritis or axial disease, functional limitation, active IBD

Requires DMARDs (sulfasalazine) ± biologic therapy coordination

SEVERE

High Activity

Destructive arthritis, severe axial disease, extra-articular complications

Biologic therapy (TNF-i, ustekinumab, vedolizumab) coordinated with gastroenterology

Treatment Strategy

Non-Pharmacological Management

Physiotherapy and exercise are essential for joint mobility and function. Regular low-impact exercise (swimming, walking, cycling) recommended. Posture correction and spinal mobility exercises for axial disease. Dietary management and nutritional support coordinated with gastroenterology for IBD control.

NSAIDs — Use with Caution

NSAIDs are effective for peripheral and axial joint pain but carry significant risk of exacerbating IBD activity, particularly in Crohn's disease. Use the lowest effective dose for the shortest duration. Avoid in active IBD flares. Celecoxib (COX-2 inhibitor) may be better tolerated but still not risk-free. Coordinate NSAID use with gastroenterologist.

Corticosteroids

Systemic corticosteroids (prednisolone 20–40 mg daily) used for acute severe flares of both IBD and peripheral arthritis. Intra-articular corticosteroid injection for single inflamed joints. Not appropriate for long-term maintenance due to side effects. Budesonide (topically active) useful for IBD without major systemic arthritis benefit.

Directed Therapy

Conventional DMARDs

💊

Sulfasalazine

Salazopyrin® · DMARD · Peripheral arthritis

Adult Dose2–3 g daily in divided doses

Paediatric40–60 mg/kg/day (max 2 g/day)

RouteOral

FrequencyTwo to four times daily

DurationOngoing; review 3–6 monthly

Renal Adj.Reduce dose if eGFR <30

Hepatic Adj.Caution; monitor LFTs

PBS Status✓ PBS Listed

💉

Infliximab

Remicade®, Inflectra® · TNF-α Inhibitor

Adult Dose5 mg/kg IV at 0, 2, 6 weeks, then every 8 weeks

Paediatric5 mg/kg (Crohn's disease >6 years)

RouteIntravenous infusion

FrequencyEvery 8 weeks (maintenance)

DurationOngoing until remission or loss of response

Renal Adj.No adjustment required

Hepatic Adj.Caution in hepatic impairment

PBS StatusPBS Authority Required

💉

Adalimumab

Humira®, Idacio® · TNF-α Inhibitor

Adult Dose160 mg SC loading, then 80 mg at 2 weeks, then 40 mg every 2 weeks

PaediatricWeight-based; see product information

RouteSubcutaneous injection

FrequencyEvery 2 weeks (maintenance)

DurationOngoing

Renal Adj.No adjustment required

Hepatic Adj.No adjustment required

PBS StatusPBS Authority Required

💉

Ustekinumab

Stelara® · IL-12/23 Inhibitor

Adult Dose~6 mg/kg IV single dose, then 90 mg SC every 8 or 12 weeks

PaediatricNot routinely approved in children for IBD

RouteIV (induction), SC (maintenance)

FrequencyEvery 8–12 weeks (maintenance)

DurationOngoing; assess response at 16 weeks

Renal Adj.No adjustment required

Hepatic Adj.No adjustment required

PBS StatusPBS Authority Required

Acute Management

Acute Peripheral Arthritis Flare

Assess both joint and bowel disease activity simultaneously. For isolated joint flare with quiescent IBD: consider short-course NSAIDs (lowest dose, shortest duration), intra-articular corticosteroid injection for single large joint, or systemic prednisolone 20–30 mg daily with rapid taper over 2–4 weeks.

Combined IBD and Arthritis Flare

Systemic corticosteroids address both IBD and peripheral arthritis simultaneously. Assess biologic therapy adequacy — consider dose escalation or switch if on existing biologic. Urgent gastroenterology review essential. Avoid NSAIDs in IBD flare. For hospitalised patients, consider IV methylprednisolone.

Uveitis

Urgent ophthalmology referral for acute anterior uveitis. Topical corticosteroids and mydriatics first-line. Systemic immunosuppression required for posterior uveitis or recurrent/chronic anterior uveitis. TNF inhibitors (infliximab or adalimumab) are first-line biologic for uveitis refractory to topical therapy.

Monitoring and Follow-up

Joint Disease Assessment

Assess joint activity (swollen/tender joint count), enthesitis sites, and functional status (HAQ) at each visit. Use BASDAI or ASDAS scores for axial disease monitoring. Track NSAID use and minimise where IBD activity present. Review imaging (sacroiliac X-ray, MRI spine) 1–2 yearly for axial disease or as clinically indicated.

IBD-Specific Monitoring

Coordinate with gastroenterology for IBD disease activity assessment (Harvey-Bradshaw Index for Crohn's, partial Mayo Score for UC). Faecal calprotectin and CRP for mucosal inflammation monitoring. Colonoscopy as clinically indicated. Ensure biologic therapy chosen addresses both gut and joint disease where possible.

Biologic Monitoring

If on TNF inhibitors: FBC, LFTs, renal function at baseline, then 6-weekly for 3 months, then 3-monthly. Annual TB screening. Monitor for opportunistic infections, demyelination, worsening heart failure. Drug-level monitoring (trough levels) to guide dose escalation for inadequate response.

Special Populations

👶 Paediatric IBD-Related Arthritis

NSAID UseUse with extreme caution or avoid — risk of IBD flare. Intra-articular corticosteroids preferred for isolated joint involvement.

Biologic TherapyInfliximab and adalimumab approved for paediatric Crohn's disease. Often address both gut and joint disease simultaneously. Monitor growth and development.

Steroid Side EffectsProlonged corticosteroid use risks growth retardation, osteoporosis, and adrenal suppression. Minimise use; use enteric budesonide where possible.

🤰 Pregnancy

NSAIDsAvoid in third trimester. Use sparingly in first and second trimesters only if essential.

SulfasalazineSafe in pregnancy; supplement with folate 5 mg daily. Compatible with breastfeeding.

TNF InhibitorsAdalimumab and infliximab compatible with pregnancy and breastfeeding. Discuss risk of neonatal immunosuppression with certolizumab preferred in third trimester due to minimal placental transfer.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

IBD prevalence in Aboriginal and Torres Strait Islander communities is not well characterised but emerging evidence suggests increasing rates, particularly in urban and peri-urban populations. Enteropathic arthritis as an IBD complication may therefore be an underrecognised condition. Delayed diagnosis of both IBD and associated arthritis is a significant concern.

Access to Specialist Services

Gastroenterology and rheumatology services are scarce in regional and remote areas. Telehealth consultation and shared-care models between remote primary health services and metropolitan specialists should be established. Aboriginal liaison officers can facilitate care coordination.

Diagnostic Barriers

Colonoscopy and MRI access is limited in many communities. Non-invasive monitoring (faecal calprotectin, CRP) should be maximised. Patient transport assistance and accommodation funding should be explored for specialist procedures.

Biologic Access

Biologic therapies require specialist prescription, cold-chain storage, and regular monitoring which can be difficult in remote settings. Explore community nursing support, patient transport, and telehealth monitoring to maintain biologic access.

Comorbidity Burden

High rates of smoking, nutritional deficiency, stress-related gut conditions, and infections may complicate IBD and EnA management. Holistic and culturally safe care addressing social determinants of health is essential.

Antimicrobial Stewardship

Antibiotic Use in Enteropathic Arthritis

Antibiotics do not have a primary role in managing EnA. Treat identified infections (e.g., Clostridioides difficile superinfection in IBD) with appropriate targeted therapy. Avoid empirical antibiotic use for arthritis flares without infectious trigger. NSAIDs, DMARDs, and biologics are the appropriate disease-modifying therapies.

Screen for Clostridioides difficile in IBD flares before escalating immunosuppression
TB screening (IGRA or Mantoux) mandatory before initiating TNF inhibitors
Hepatitis B and C serology required before biologic therapy — treat or manage accordingly
Prophylactic co-trimoxazole considered in highly immunosuppressed patients (dual/triple immunosuppression)

⚠️

Important: Do not use antibiotics to treat IBD flares without a confirmed infection. Overuse of antibiotics exacerbates gut dysbiosis, worsening IBD activity and potentially triggering arthritis flares.

References

01
Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol. 2009;15(20):2449-2455.
02
Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease. Gut. 1998;42(3):387-391.
03
Peluso R, Manguso F, Vitiello M, et al. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015;6(2):65-77.
04
Crohn's and Colitis Australia. IBD in Australia: 2021 National Report. Notting Hill: CCA; 2021. Available from: https://www.crohnsandcolitis.com.au
05
Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239-254.
06
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease. Am J Gastroenterol. 2001;96(4):1116-1122.
07
van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-991.
08
Australian Rheumatology Association. Management of Inflammatory Arthritis Clinical Practice Guidelines. Sydney: ARA; 2023.
09
Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut. 2011;60(12):1739-1753.
10
Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res. 2002;4(5):307-321.